Just before the May 5 trial date set for Novartis and Incyte to finally hash out their Jakafi royalty dispute in court, the ...

The laboratory services company has agreed to purchase certain assets of Incyte's clinical and anatomic pathology testing ...

Incyte Corp raised the annual sales forecast for its blood cancer drug Jakafi on Tuesday, and said it expects minimal impact from U.S. tariffs due to its flexibility in sourcing supplies. CEO Hervé ...

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Incyte INCY in the ...

Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to ...

Incyte Corp raised its annual sales forecast for its blood cancer treatment Jakafi on Tuesday, after robust sales of the drug helped it beat Wall Street estimates for quarterly results. Apart from ...

Shares of Incyte Corp. INCY slid 1.01% to $62.03 Thursday, on what proved to be an all-around positive trading session for ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations , with sales up 19.5% year on year to $1.05 billion. Its non ...

The Wilmington, Delaware-based company said it had profit of 80 cents per share. Earnings, adjusted for one-time gains and costs, came to $1.16 per share. The results topped Wall Street expectations.

Achieved $20.0 million in Revuforj net revenue in the first quarter of 2025, the first full quarter of the U.S. launch. Revuforj was launched in the U.S. in late November 2024 for the treatment of ...